tag:blogger.com,1999:blog-4599326694255740220.comments2022-02-15T19:21:55.497-05:00What the Pharma?Ronak Savlahttp://www.blogger.com/profile/16068437679427623681noreply@blogger.comBlogger9125tag:blogger.com,1999:blog-4599326694255740220.post-60443484658213147032022-02-15T19:21:55.497-05:002022-02-15T19:21:55.497-05:00This could be a ground breaking treatment. Keep g...This could be a ground breaking treatment. Keep going, you are almost there. <a href="https://polarbearmeds.com/drug-infosheet/ozempic/" rel="nofollow">Ozempic pen</a>Sem Edward Osterhttps://www.blogger.com/profile/04797671693941471588noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-43285932307680864842021-06-13T00:37:03.240-04:002021-06-13T00:37:03.240-04:00Hello, this weekend is good for me, since this tim...Hello, this weekend is good for me, since this time i am reading this enormous informative article here at my home. <a href="https://buycanadianinsulin.com/product/ozempic-semaglutide-injection/" rel="nofollow">Ozempic</a><br />sid seohttps://www.blogger.com/profile/12338695106840420249noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-85792165302718696752014-08-17T20:47:22.020-04:002014-08-17T20:47:22.020-04:00Can you please give me the reference for the "...Can you please give me the reference for the "Time to Peak Insulin Level" graph? I would love to use it in a presentation but need the proper citation. Thank you!erin♥https://www.blogger.com/profile/06845636404414220247noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-86939632663076272122011-07-06T18:02:26.919-04:002011-07-06T18:02:26.919-04:00My argument not in favor of palifosfamide is that ...My argument not in favor of palifosfamide is that soft tissue sarcoma is a rare cancer; it accounts for 1% of all cancers. I don't see it generating the revenues to fund all of the other projects. The biggest boost would have been good results from oral palifosfamide therapy, which was in Phase 1. The study has been suspended (http://goo.gl/4V4pH). Oral therapy would be a big plus for the treatment for other cancers for which palifosfamide showed good in vitro activity.<br /><br />The Yervoy results were from Phase 3 trials, not Phase 1b as with AD-IL-12. It is typical that Phase 1 and 2 trials yield better results than Phase 3 due to various factors including increased heterogeneity of the study population. ZIOP includes Stable Disease (SD) as part of overall/objective response (OR); the standard is to use only complete response and partial response when calculating OR. <br /><br />Also, Yervoy is the 1st drug approved for the treatment of unresectable or metastatic melanoma. Therefore, it has a lower bar than future drugs because patients have no other viable options. Vemurafenib from Plexxikon/ Roche is poised to set a very high bar. However, this drug can be used in only in patients with a BRAF mutation (~60% of melanoma patients). <br /><br />The target population for Yervoy is very sick. They have no other options and the median survival is less than 1 year. Possible death due to SAEs is found on the labels of many chemotherapeutics. Deaths from Yervoy are due to T-cell mediated immune reactions. Successful treatment with AD-IL-12 will include T-cell mediated immune reactions since IL-12 induces T-cell maturation and differentiation. The adenoviral vector can also induce T-cell mediated immune response. Phase 1b trials are short and will not reveal longer term toxicities seen in Phase 3 trials.Ronak Savlahttps://www.blogger.com/profile/16068437679427623681noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-83141032537092459672011-07-06T10:50:43.397-04:002011-07-06T10:50:43.397-04:00YERVOY was approved with about a 26% overall respo...YERVOY was approved with about a 26% overall response rate; a fact you can check. Yet you describe a 50% response rate for ZIOPHARM's AD-IL-12 as "unacceptable." That seems a bit odd; really a total misread. Apparently you are unaware of the YERVOY response rate, or you just choose to overlook bad facts give YERVOY is FDA approved? (Bad if you are parroting the arguments of the shorts).<br /><br />Also -- from its label: "YERVOY (ipilimumab) can cause serious side effects in many parts of your body which can lead to death."<br /><br />The side effect profile for YERVOY appears more toxic with SAEs leading to death, and its response rate is well under 50%!<br /><br />Separately, you don't seem to understand that palifosfamide is a less toxic, hopefully safer version of ifosfamide with comparable efficacy. The problem with ifos is not its clinical response performance; but rather is its toxic side effect profile. The Phase II palifosfamide study in Soft-Tissue Sarcoma was judged a "best of ASCO."<br /><br />etc. etc.<br /><br />This analysis is just a cheap shot at ZIOPHARM (and Intrexon) and lacking the scientific rigor you purport to attain as "oracle of pharma."<br /><br />You are an oracle in your own mind, but that is about it. The shorts create a net buying opportunity to the extent they can pass garbage on as fact.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-51415120242088301332011-07-04T16:16:09.810-04:002011-07-04T16:16:09.810-04:00Thanks for your comment. First, I have no positio...Thanks for your comment. First, I have no position on the stock and do not plan to initiate one. The author of the article you mention is long on ZIOP. The author just summarizes the presentation at NYC. The author is also not a scientist. I was at the NYC meeting and spoke to several scientists and all of us were not impressed. <br /><br />Of course the speakers will not mention anything negative about their approach. They may impress those who are not scientists, but they cannot support their science nor explain the mechanism to those of us who work in the area. <br /><br />ZIOP and Intrexon champion that they are designing faster methods for drug development. What are other companies doing? Do you think that they like slow and expensive drug development processes? The best available methods are high throughput screening and RNA interference to learn gene-protein function. There's nothing in ZIOP and Intrexon's approach that will accelerate the drug development process in the next decade. <br /><br />The approach to use a viral vector to insert a gene into cells is not new and has been tried thousands of times. Read about Jesse Gelsinger, who died due to a massive immune attack induced by a viral vector. There is public resistance against gene therapy. This opened the door for RNA interference as a substitute. <br /><br />Also, I have been working on development of cancer vaccines for last 3 years. I have read clinical and pre-clinical studies for cancer vaccines and drugs that stimulate the immune system. If you look at the results from Vemurafenib, Yervoy, or Allovectin, you'll notice how much superior they are compared to ZIOP's candidate. Yervoy is already approved and the 2 other drugs are at a more advanced stage than ZIOP.<br /><br />A new drug candidate is almost always treated in patients who have failed current forms of treatment. That's not an excuse for poor results. <br /><br />The reason that "synthetic biology" platform only treats visible tumors is simple. The DNA is injected intratumorally. You can only inject where you see a tumor. If all the cells in the tumors are transfected and begin secreting IL-12, they will be targeted and may be killed. Untransfected tumors are not detected or killed in any way.Ronak Savlahttps://www.blogger.com/profile/16068437679427623681noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-86914615599720249012011-07-04T14:34:56.290-04:002011-07-04T14:34:56.290-04:00http://seekingalpha.com/article/277382-ziopharm-sm...http://seekingalpha.com/article/277382-ziopharm-small-molecules-meet-next-generation-synthetic-biology<br /><br /><br /><br />I am not sure you were at the meeting in NYC. See above for a different point of view. Did you hear Dr. Read say "Vaccine -like effect"---not sure where you came to the conclusion that it would only treat visable tumors. Also, these melanona patients had already failed other forms of treatment(you failed to mention that) so where is your justification to say the results were very disappointing??? <br /><br />Methinks you might be short?? If so, I sincerely hope you cover soon.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-51989029228937205322011-02-18T01:24:09.608-05:002011-02-18T01:24:09.608-05:00Hi,
I have been searching for this information an...Hi,<br /><br />I have been searching for this information and finally found it. Thanks! <br /><br /><a href="http://www.imgenex.com/" rel="nofollow">Foxp3 regulators</a>Imgenexhttps://www.blogger.com/profile/10042237812536700574noreply@blogger.comtag:blogger.com,1999:blog-4599326694255740220.post-19252469071702792382011-01-18T02:25:04.822-05:002011-01-18T02:25:04.822-05:00Amgen's is a fully human monoclonal antibody t...Amgen's is a fully human monoclonal antibody that is FDA approved for the treatment of osteoporosis and prevention of skeletal related events in patients with bone metastasis. Thanks....<br /><br /><a href="http://imgenex.com/" rel="nofollow">Antibody</a>Imgenexhttps://www.blogger.com/profile/10042237812536700574noreply@blogger.com